Ubs Group Ag Marker Therapeutics, Inc. Call Options Transaction History
Ubs Group Ag
- $452 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding MRKR
# of Institutions
5Shares Held
475KCall Options Held
0Put Options Held
0-
Act Capital Management, LLC Wayne, PA354KShares$1.1 Million0.18% of portfolio
-
Ar Asset Management Inc73.7KShares$228,4700.05% of portfolio
-
Personal Capital Advisors Corp25.7KShares$79,7070.0% of portfolio
-
American Portfolios Advisors Holbrook, NY21.2KShares$65,6270.0% of portfolio
-
Concourse Financial Group Securities, Inc. Birmingham, AL0Shares$00.0% of portfolio
About Marker Therapeutics, Inc.
- Ticker MRKR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,599,200
- Market Cap $259M
- Description
- Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufact...